Lao, Kim S. J.
Wong, Angel Y. S.
Wong, Ian C. K.
Besag, Frank M. C.
Chang, W. C.
Lee, Edwin H. M.
Chen, Eric Y. H.
Blais, Joseph E.
Chan, Esther W. http://orcid.org/0000-0002-7602-9470
Funding for this research was provided by:
General Research Fund, Research Grants Council, Hong Kong (17111615)
Early Career Scheme, Research Grants Council, Hong Kong (789813)
Article History
First Online: 8 January 2020
Compliance with Ethical Standards
:
: This study was supported by the General Research Fund, Research Grants Council, Hong Kong (project reference 17111615) and partially funded by the Early Career Scheme, Research Grants Council, Hong Kong (project reference 789813). The funders had no role in the design, analysis, interpretation, or publication of this study.
: All authors declare that no other support has been received from any organization for the submitted work; no other financial relationships exist with any organizations that might have an interest in the submitted work in the previous 3 years; no other relationships exist or activities have been undertaken that could appear to have influenced the submitted study. KSJL was formerly employed by the University of Hong Kong, where most of the work was completed, and is currently employed by MRL, MSD China at submission. Outside the submitted work, AYSW has received Institutional Strategic Support Fund 3 Pump Priming Grant, and is currently supported by British Heart Foundation Immediate Postdoctoral Basic Science Research Fellowship. EWC has received research funding from the Wellcome Trust, UK; the National Natural Science Fund of China, China; The Hong Kong Research Grants Council, The Research Fund Secretariat of the Food and Health Bureau, the Narcotics Division of the Security Bureau of HKSAR, Hong Kong; Bristol-Myers Squibb, Pfizer, Bayer, and Janssen, a division of Johnson & Johnson, and Takeda for work unrelated to this study. ICKW has received grants from the Research Grants Council (RGC, Hong Kong), the Innovative Medicines Initiative (IMI), Shire, Janssen-Cilag, Eli-Lily, Pfizer, Bayer, and the European Union FP7 program outside the submitted work; is a member of the National Institute for Health and Care Excellence (NICE) ADHD guideline group and the British Association for Psychopharmacology ADHD guideline group; and an advisor to Shire. EYHC has completed work for Otsuka, Janssen, and DSK Biopharma. FMCB, WCC, EHML, and JEB have no conflicts of interest that are directly relevant to the content of this article.
: Not applicable.